The shift to pan-mutation PI3Kα inhibition is real

Novartis paying $2bn for Synnovation’s pan-mutant PI3Kα inhibitor SNV4818 was another vote of no-confidence in the mutation-specific approach being pursued by OnKure, and on Friday reality hit. OnKure has revealed the discontinuation of its H1047R mutation-specific molecule OKI-219, and a focus on a pan-mutation project instead. OnKure was facing a key catalyst, with the imminent readout of OKI-219’s phase 1 Pikture-01 trial in breast cancer; in the event it’s declined to reveal any data, saying only that recruitment into two Pikture-01 cohorts had been completed, and that “mature” results would be presented later this year. In the meantime, it will no longer develop OKI-219 independently. Shares opened off 16% on this news, though on the plus side OnKure raised $150m from private investors, a sum it will now put towards developing a still preclincial pan-mutation (PI3Kα wild-type sparing) molecule, OKI-345. Such a move not only follows Novartis's endorsement, but also mirrors Lilly’s discontinuation of LY3849524 and switch to the Scorpion-originated tersolisib. Still in the mutation-specific game is Cogent with CGT6297, though it's working preclinically on pan-mutant molecules. Pan-mutation PI3Kα inhibitors include Relay's zovegalisib and Totus's covalent molecule TOS-358.